<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BETIMOL- timolol solution/ drops </strong><br>Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) (968937719)<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">3220660/7
</p>
<p><span class="Italics">0.25%, 0.5%</span></p>
<p><span class="Bold Italics">BETIMOL</span><span class="Bold Italics"><span class="Sup">®</span></span></p>
<p><span class="Italics">(timolol ophthalmic<br>solution)0.25%,0.5%</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Betimol<span class="Sup">®</span> (timolol ophthalmic solution), 0.25% and 0.5%, is a non-selective beta-adrenergic antagonist for ophthalmic use. The chemical name of the active ingredient is (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol. Timolol hemihydrate is the levo isomer. Specific rotation is [α]<span class="Sup">25
</span><span class="Sub">405nm</span>=-16° (C=10% as the hemihydrate form in 1N HCl).
</p>
<p>The molecular formula of timolol is Formula C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S and its structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f&amp;name=bet09-0000-01.jpg">
</div>
<p>Timolol (as the hemihydrate) is a white, odorless, crystalline powder which is slightly soluble in water and freely soluble in ethanol. Timolol hemihydrate is stable at room temperature.
</p>
<p>Betimol<span class="Sup">®</span> is a clear, colorless, isotonic, sterile, microbiologically preserved phosphate buffered aqueous solution.
</p>
<p>It is supplied in two dosage strengths, 0.25% and 0.5%.
</p>
<p>Each mL of Betimol<span class="Sup">®</span> 0.25% contains 2.56 mg of timolol hemihydrate equivalent to 2.5 mg timolol.
</p>
<p>Each mL of Betimol<span class="Sup">®</span> 0.5% contains 5.12 mg of timolol hemihydrate equivalent to 5.0 mg timolol.
</p>
<p>Inactive ingredients: monosodium and disodium phosphate dihydrate to adjust pH (6.5 - 7.5) and water for injection, benzalkonium chloride 0.01% added as preservative.
</p>
<p>The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of Betimol<span class="Sup">®</span> is 260 to 320 mOsmol/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Timolol is a non-selective beta-adrenergic antagonist.
</p>
<p>It blocks both beta<span class="Sub">1</span>-and beta<span class="Sub">2</span>-adrenergic receptors. Timolol does not have significant intrinsic sympathomimetic activity, local anesthetic (membrane-stabilizing) or direct myocardial depressant activity.
</p>
<p>Timolol, when applied topically in the eye, reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous visual field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.
</p>
<p>In general, beta-adrenergic blocking agents reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> both in healthy subjects and patients with heart diseases. In patients with severe impairment of myocardial function, beta-adrenergic receptor blocking agents may inhibit sympathetic stimulatory effect necessary to maintain adequate cardiac function. In the bronchi and bronchioles, beta-adrenergic receptor blockade may also increase airway resistance because of unopposed parasympathetic activity.
</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics
</h2>
<p class="First">When given orally, timolol is well absorbed and undergoes considerable first pass metabolism. Timolol and its metabolites are primarily excreted in the urine. The half-life of timolol in plasma is approximately 4 hours.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s5"></a><a name="section-3.2"></a><p></p>
<h2>Clinical Studies
</h2>
<p class="First">In two controlled multicenter studies in the U.S., Betimol<span class="Sup">®</span> 0.25% and 0.5% were compared with respective timolol maleate eyedrops. In these studies, the efficacy and safety profile of Betimol<span class="Sup">®</span> was similar to that of timolol maleate.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Betimol<span class="Sup">®</span> is indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Betimol<span class="Sup">®</span> is contraindicated in patients with overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">As with other topically applied ophthalmic drugs, Betimol<span class="Sup">®</span> is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> have been reported following systemic or topical administration of beta-adrenergic blocking agents.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.
</p>
<p>In patients without a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Betimol<span class="Sup">®</span> should be discontinued at the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.2"></a><p></p>
<p class="First">Obstructive Pulmonary Disease: Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g. <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> which are contraindications) should in general not receive beta-blocking agents.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.3"></a><p></p>
<p class="First">Major Surgery: The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to a major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergicaliy mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents is recommended. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of beta-adrenergic agonists.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-6.4"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus: Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-6.5"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>: Beta-adrenergic blocking agents may mask certain clinical signs (e.g. <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s14"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s15"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Because of the potential effects of beta-adrenergic blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with Betimol<span class="Sup">®</span>, alternative therapy should be considered.
</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (See <a href="#s16">PRECAUTIONS, Information for Patients</a>.)
</p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>: Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g. <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Beta-adrenergic blocking agents have been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.
</p>
<p>In angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the goal of the treatment is to reopen the angle. This requires constricting the pupil. Betimol<span class="Sup">®</span> has no effect on the pupil. Therefore, if timolol is used in angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, it should always be combined with a miotic and not used alone.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="e16"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>: While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.
</p>
<p>The preservative benzalkonium chloride may be absorbed by soft contact lenses. Patients who wear soft contact lenses should wait 5 minutes after instilling Betimol<span class="Sup">®</span> before they insert their lenses.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s16"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.
</p>
<p>Patients should also be instructed that ocular solutions can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions. (See <a href="#s15">PRECAUTIONS, General</a>.)
</p>
<p>Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 5 minutes apart.
</p>
<p>Patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product (See <a href="#s7">CONTRAINDICATIONS</a>.)
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s17"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-7.3.1"></a><p></p>
<p class="First">Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Betimol<span class="Sup">®</span> should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta-blockade.
</p>
<p>Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-7.3.2"></a><p></p>
<p class="First">Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.3.3"></a><p></p>
<p class="First">Calcium antagonists: Caution should be used in the co-administration of beta-adrenergic blocking agents and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, co-administration should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.3.4"></a><p></p>
<p class="First">Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
</p>
<p>Injectable Epinephrine: (See <a href="#e16">PRECAUTIONS, General, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a>.)
</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s22"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenicity of timolol (as the maleate) has been studied in mice and rats. In a two-year study orally administrated timolol maleate (300mg/kg/day) (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose) in male rats caused a significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span>; the lower doses, 25 mg or 100 mg/kg daily did not cause any changes.
</p>
<p>In a life span study in mice the overall incidence of neoplasms was significantly increased in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Furthermore, significant increases were observed in the incidences of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>, as well as mammary adenocarcinomas. These changes were not seen at the daily dose level of 5 or 50 mg/kg (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). For comparison, the maximum recommended human oral dose of timolol maleate is 1 mg/kg/day.
</p>
<p>Mutagenic potential of timolol was evaluated <span class="Italics">in vivo</span> in the micronucleus test and cytogenetic assay and <span class="Italics">in vitro</span> in the neoplastic cell transformation assay and Ames test. In the bacterial mutagenicity test (Ames test) high concentrations of timolol maleate (5000 and 10,000 g/plate) statistically significantly increased the number of revertants in <span class="Underline"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> TA100, but not in the other three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> tested. However, no consistent dose-response was observed nor did the number of revertants reach the double of the control value, which is regarded as one of the criteria for a positive result in the Ames test, <span class="Italics">in vivo</span> genotoxicity tests (the mouse micronucleus test and cytogenetic assay) and <span class="Italics">in vitro</span> the neoplastic cell transformation assay were negative up to dose levels of 800 mg/kg and 100 g/mL, respectively.
</p>
<p>No adverse effects on male and female fertility were reported in rats at timolol oral doses of up to 150 mg/kg/day (21,000 times the systemic exposure following the maximum recommended human ophthalmic dose).
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s23"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy Teratogenic effects:
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-7.5.1"></a><p></p>
<p class="First">Category C: <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> of timolol (as the maleate) after oral administration was studied in mice and rabbits. No <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> were reported in mice or rabbits at a daily oral dose of 50 mg/kg (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose in this case without apparent maternotoxicity.
</p>
<p>There are no adequate and well-controlled studies in pregnant women. Betimol<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s25"></a><a name="section-7.6"></a><p></p>
<h2>Nursing mothers:
</h2>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from timolol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s26"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric use:
</h2>
<p class="First">Safety and efficacy in pediatric patients have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s27"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The most frequently reported ocular event in clinical trials was burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> on instillation and was comparable between Betimol<span class="Sup">®</span> and timolol maleate (approximately one in eight patients).
</p>
<p>The following adverse events were associated with use of Betimol<span class="Sup">®</span> in frequencies of more than 5% in two controlled, double-masked clinical studies in which 184 patients received 0.25% or 0.5% Betimol<span class="Sup">®</span>:
</p>
<p><span class="Bold">OCULAR:</span></p>
<p><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eyes</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in the eye, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival injection</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.
</p>
<p><span class="Bold">BODY AS A WHOLE:</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.
</p>
<p>The following side effects were reported in frequencies of 1 to 5%:
</p>
<p><span class="Bold">OCULAR:</span></p>
<p><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">epiphora</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, blurred or <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, corneal fluorescein staining, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>.
</p>
<p><span class="Bold">BODY AS A WHOLE:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in extremities.
</p>
<p><span class="Bold">CARDIOVASCULAR:</span></p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>.
</p>
<p><span class="Bold">DIGESTIVE:</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>.
</p>
<p><span class="Bold">METABOLIC/NUTRITIONAL:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>.
</p>
<p><span class="Bold">NERVOUS SYSTEM/PSYCHIATRY:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.
</p>
<p><span class="Bold">RESPIRATORY:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory infection</span> and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.
</p>
<p>In addition, the following adverse reactions have been reported with ophthalmic use of beta blockers:
</p>
<p><span class="Bold">OCULAR:</span></p>
<p><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">blepharoptosis</span>, decreased corneal sensitivity, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> and <span class="product-label-link" type="condition" conceptid="434337" conceptname="Retinal vascular disorder">retinal vascular disorder</span>.
</p>
<p><span class="Bold">BODY AS A WHOLE:</span></p>
<p><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>.
</p>
<p><span class="Bold">CARDIOVASCULAR:</span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.
</p>
<p><span class="Bold">DIGESTIVE:</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.
</p>
<p><span class="Bold">ENDOCRINE:</span></p>
<p>Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in insulin dependent diabetics (See <a href="#s8">WARNINGS</a>).
</p>
<p><span class="Bold">NERVOUS SYSTEM/PSYCHIATRY:</span></p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.
</p>
<p><span class="Bold">RESPIRATORY:</span></p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>.
</p>
<p><span class="Bold">SKIN:</span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> including localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s28"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">No information is available on overdosage with Betimol<span class="Sup">®</span> Symptoms that might be expected with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of a beta-adrenergic receptor blocking agent are <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s29"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Betimol<span class="Sup">®</span> Ophthalmic Solution is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Betimol<span class="Sup">®</span> in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) twice a day.
</p>
<p>If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.
</p>
<p>Since in some patients the pressure-lowering response to Betimol<span class="Sup">®</span> may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Betimol<span class="Sup">®</span>.
</p>
<p>Dosages above one drop of 0.5 percent Betimol<span class="Sup">®</span> twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s30"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Betimol<span class="Sup">®</span> (timolol ophthalmic solution) is a clear, colorless solution.
</p>
<p>Betimol<span class="Sup">®</span> 0.25% is supplied in a white, opaque, plastic, ophthalmic dispenser bottle with a controlled drop tip as follows:
</p>
<table width="100%">
<col align="left" width="37.867%">
<col align="left" width="18.000%">
<col align="left" width="44.133%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="bottom">NDC 76478-001-05
</td>
<td align="left" valign="bottom">5 mL
</td>
<td align="left" valign="bottom">fill in 5 cc container
</td>
</tr>
<tr>
<td align="left" valign="bottom">NDC 76478-001-10
</td>
<td align="left" valign="bottom">10 mL
</td>
<td align="left" valign="bottom">fill in 11 cc container
</td>
</tr>
<tr class="Last">
<td align="left" valign="bottom">NDC 76478-001-15
</td>
<td align="left" valign="bottom">15 mL
</td>
<td align="left" valign="bottom">fill in 15 cc container
</td>
</tr>
</tbody>
</table>
<p>Betimol<span class="Sup">®</span> 0.5% is supplied in a white, opaque, plastic, ophthalmic dispenser bottle with a controlled drop tip as follows:
</p>
<table width="100%">
<col align="left" width="37.867%">
<col align="left" width="18.000%">
<col align="left" width="44.133%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="bottom">NDC 76478-002-05
</td>
<td align="left" valign="bottom">5 mL
</td>
<td align="left" valign="bottom">fill in 5 cc container
</td>
</tr>
<tr>
<td align="left" valign="bottom">NDC 76478-002-10
</td>
<td align="left" valign="bottom">10 mL
</td>
<td align="left" valign="bottom">fill in 11 cc container
</td>
</tr>
<tr class="Last">
<td align="left" valign="bottom">NDC 76478-002-15
</td>
<td align="left" valign="bottom">15 mL
</td>
<td align="left" valign="bottom">fill in 15 cc container
</td>
</tr>
</tbody>
</table>
<p>Rx Only
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s31"></a><a name="section-11.1"></a><p></p>
<h2>STORAGE
</h2>
<p class="First">Store between 15° to 25°C (59° to 77°F). Do not freeze. Protect from light.
</p>
<p><span class="Bold">AKORN<br>Distributed by</span>: Akorn, Inc.<br>Lake Forest, IL 60045
</p>
<p><span class="Bold">OAK<br>Manufactured for:</span> Oak Pharmaceutical
</p>
<p><span class="Bold">Made in Finland</span></p>
<p>OPBT00N Rev. 02/14
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s32"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 76478-001-05
</p>
<p>BETIMOL<span class="Sup">®</span></p>
<p>(timolol ophthalmic
</p>
<p>solution) 0.25%
</p>
<p>Timolol equivalent (timolol
</p>
<p>hemihydrate 2.56 mg/mL)
</p>
<p>5 mL
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f&amp;name=bet09-0000-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s33"></a><a name="section-13"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 76478-001-05
</p>
<p>BETIMOL<span class="Sup">®</span></p>
<p>(timolol ophthalmic
</p>
<p>solution) 0.25%
</p>
<p>Timolol equivalent (timolol
</p>
<p>hemihydrate 2.56 mg/mL)
</p>
<p>Rx Only
</p>
<p>5 mL
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f&amp;name=bet09-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s34"></a><a name="section-14"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 76478-002-05
</p>
<p>BETIMOL<span class="Sup">®</span></p>
<p>(timolol ophthalmic
</p>
<p>solution) 0.5%
</p>
<p>Timolol equivalent (timolol
</p>
<p>hemihydrate 5.12 mg/mL)
</p>
<p>5 mL
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f&amp;name=bet09-0000-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s35"></a><a name="section-15"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 76478-002-05
</p>
<p>BETIMOL<span class="Sup">®</span></p>
<p>(timolol ophthalmic
</p>
<p>solution) 0.5%
</p>
<p>Timolol equivalent (timolol
</p>
<p>hemihydrate 5.12 mg/mL)
</p>
<p>Rx Only
</p>
<p>5 mL
</p>
<div class="Figure">
<a name="f05"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d7acd55-33b1-4a24-99ae-01f87b0dca1f&amp;name=bet09-0000-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BETIMOL 		
					</strong><br><span class="contentTableReg">timolol solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76478-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Timolol</strong> (Timolol Anhydrous) </td>
<td class="formItem">Timolol Anhydrous</td>
<td class="formItem">2.56 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76478-001-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76478-001-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:76478-001-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020439</td>
<td class="formItem">01/02/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BETIMOL 		
					</strong><br><span class="contentTableReg">timolol solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76478-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Timolol</strong> (Timolol Anhydrous) </td>
<td class="formItem">Timolol Anhydrous</td>
<td class="formItem">5.12 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76478-002-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76478-002-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:76478-002-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:76478-002-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020439</td>
<td class="formItem">01/02/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) (968937719)
							(968937719)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d1c26bc8-7ca6-4e46-affc-1847bd82e720</div>
<div>Set id: 3d7acd55-33b1-4a24-99ae-01f87b0dca1f</div>
<div>Version: 1</div>
<div>Effective Time: 20140327</div>
</div>
</div> <div class="DistributorName">Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) (968937719)</div></p>
</body></html>
